The Irving, Texas-based McKesson Corporation, with a market capitalization of nearly $105.6 billion, has seen its stock climb 39.8% over the past 52 weeks and 51% year-to-date, outperforming the S&P 500 Index. In the healthcare sector, McKesson has surged 7.5% over the past 52 weeks and 10.9% YTD, surpassing the S&P 500 Healthcare Sector SPDR. Following its second-quarter results for fiscal year 2026, McKesson’s revenue rose 10.1% YoY to $103.2 billion, with EPS increasing 377% annually to $8.92. Analysts forecast 17% EPS growth for the fiscal year ending in March 2026, with a consensus “Strong Buy” rating among analysts.

Analysts are confident about McKesson’s future, with a “Strong Buy” consensus rating and a price target increase to $927 from Baird analyst Eric Coldwell. The average price target of $921.73 represents potential upside of 7.1%, while the Street-high target of $1000 from TD Cowen analyst Charles Rhyee suggests room for potential upside of 16.2%. The firm maintains a “Buy” rating, highlighting the company’s solid long-term fundamentals.

Read more at Barchart: Are Wall Street Analysts Bullish on McKesson Stock?